TABLE 1.
Effect of 2 weeks of treatment with Murabutide on plasma viral loads in hu-PBL-SCID micea
| Expt no. | No. of mice/group | Plasma viral loads at week 2 of treatment
|
Plasma viral loads at week 4 of treatment
|
||
|---|---|---|---|---|---|
| PBS | Murabutide | PBS | Murabutide | ||
| 1 | 4 | 13,456 (13,077 ± 5,625) | 100 (747 ± 647) | 43,599 (38,134 ± 7,566) | 1,535 (1,531 ± 594) |
| 2 | 4 | 7,590 (16,187 ± 10,633) | 987 (886 ± 335) | 8,243 (21,774 ± 14,830) | 472 (1,080 ± 752) |
| 3 | 5 | 21,508 (77,134 ± 42,271) | 1,208 (1,247 ± 561) | 26,854 (212,989 ± 128,824) | 1,677 (2,398 ± 1,037) |
| 4 | 4 | 8,578 (15,346 ± 8,898) | 604 (657 ± 194) | 2,443 (3,254 ± 1,563) | 100 (206 ± 105) |
a
Two hours following HIV-1Ba-L infection of hu-PBL-SCID mice, groups (four or five mice per group) were treated for 13 consecutive days with PBS or with Murabutide (10 mg/kg). Plasma viral loads were evaluated at week 2 (end of treatment) and at week 4. Data shown are median plasma viral copies/milliliter, and the numbers in parentheses reflect the means ± standard errors of the mean.